Craig-Hallum Starts Aclaris Therapeutics Coverage with Buy Rating
Craig-Hallum initiates coverage of Aclaris Therapeutics with a Buy rating and $10 target, noting upcoming 2026 readouts and potential in ATI-052.
/ 904 items
#Healthcare↓
Jefferies Starts Coverage on Definium Therapeutics with Buy Rating and $30 Target
Jefferies initiated coverage on Definium Therapeutics with a Buy rating, citing strong Phase IIb results for its anxiety drug DT120 and high confidence ahead of Phase III trials.
Quince Therapeutics Halts A-T Drug Development After Phase 3 Trial Miss
Quince Therapeutics ends eDSP development for ataxia-telangiectasia after Phase 3 NEAT trial fails primary endpoints. Stock plunges 91% as company explores strategic options.
Fractyl's Weight Maintenance Study Shows Modest Results After GLP-1 Stoppage
Fractyl Health's (GUTS) REMAIN-1 study reveals limited weight maintenance benefits with Revita procedure after stopping GLP-1 medications, raising questions about effectiveness.
Steel Partners Makes $18 Acquisition Offer for InMode
Steel Partners proposes to buy 51% of InMode shares at $18 each, a 29% premium, citing poor stock performance and excessive cash holdings.
FDA Clears Serina's Advanced Parkinson's Disease Drug for Clinical Trial
Serina Therapeutics receives FDA IND clearance for SER-252, advancing toward Phase 1b clinical study for advanced Parkinson's disease treatment using POZ platform technology.